Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of P2X7 antagonist oxATP in preparation of medicament for treating myocardial ischemia injuries and hypertension/sympathetic nervous system diseases

A technology of sympathetic nerve and myocardial ischemia, which is applied in the invention of drugs for hypertension/sympathetic nervous system diseases, and the field of myocardial ischemia injury. The effect of alleviating myocardial ischemia injury

Inactive Publication Date: 2014-01-22
NANCHANG UNIV
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

P2X 7 Whether receptor antagonists can protect myocardial ischemic injury is not clear, and whether they can act on P2X of cervical sympathetic ganglion nerve cells 7 Receptors affect myocardial ischemia-induced sympathetic enhanced reflex to produce protective effects on myocardium, so far there is no literature report

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of P2X7 antagonist oxATP in preparation of medicament for treating myocardial ischemia injuries and hypertension/sympathetic nervous system diseases
  • Application of P2X7 antagonist oxATP in preparation of medicament for treating myocardial ischemia injuries and hypertension/sympathetic nervous system diseases
  • Application of P2X7 antagonist oxATP in preparation of medicament for treating myocardial ischemia injuries and hypertension/sympathetic nervous system diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0037] Using methods well known in the art, make suitable for involving cervical sympathetic ganglion or myocardial P2X 7 Oral, injection or topical application (contains, etc.) of P2X for the prevention and treatment of receptor-mediated myocardial ischemic injury (acute coronary syndrome, etc.) 7 Receptor antagonist (oxATP, etc.) preparations.

Embodiment 2

[0039] Using methods well known in the art, make suitable for involving cervical sympathetic ganglion or myocardial P2X 7 Oral, injectable, or topically applied P2X for receptor-mediated hypertension prophylaxis 7 Receptor antagonist (oxATP, etc.) preparations.

Embodiment 3

[0041] Using methods known in the art, make suitable for involving cervical sympathetic ganglion P2X 7 Oral, injectable or topical P2X for receptor-mediated prophylaxis of sympathetic nervous system disorders 7 Receptor antagonist (oxATP, etc.) preparations.

[0042] In order to better understand the essence of the present invention, the following uses P2X 7 Receptor antagonist oxATP on P2X 7 Experiments and results of receptor-mediated myocardial ischemic injury and sympathetic stimulation to prove that P2X 7 Use of the receptor antagonist oxATP.

[0043] 1. Materials and methods.

[0044] 1. Animals and groups.

[0045] Healthy Sprague-Dawley (SD) rats (body weight 180-220g), male, were provided by the Department of Experimental Animal Science, School of Medicine, Nanchang University. Rats were randomly divided into sham operation group, oxATP treatment control group, myocardial ischemia model group and ligated coronary artery P2X 7 Receptor antagonist intervention gr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of a P2X7 antagonist in preparation of medicament for treating myocardial ischemia injuries and hypertension / sympathetic nervous system diseases. Myocardial ischemia causes sympathetic excitoreflex (elevation of blood pressure, acceleration of heart rate and respiration and the like), and then myocardial ischemia injuries are aggravated. Cardiac sympathetic nervous erethism can also cause the elevation of blood pressure and then cause hypertension. The invention discloses a P2X7 receptor antagonist oxATP which can be used for reducing sympathetic nervous reflex caused by myocardial ischemia injuries and avoiding the phenomenon that myocardial ischemia and hypoxia are further aggravated due to cardiac sympathetic erethism, so that the myocardial ischemia injuries are relieved or alleviated. The hypertension can be prevented and cured by inhibiting cervical sympathetic ganglion erethism transmission. Sympathetic nervous diseases can be prevented and cured by inhibiting sympathetic erethism and related pathological processes. The mechanism of action of the oxATP in preventing and treating myocardial ischemia injuries, hypertension and sympathetic nervous lesions is as follows: the sympathetic excitation transmission mediated by cervical sympathetic ganglion P2X7 accepter is blocked, and an effect of preventing and treating the myocardial ischemia injuries, hypertension and sympathetic nervous diseases is generated.

Description

technical field [0001] The invention belongs to the technical field of inventions for use of medicines, and relates to inventions for uses of medicines for myocardial ischemia injury and hypertension / sympathetic nervous system diseases. Background technique [0002] Acute myocardial ischemia is usually caused by an imbalance between myocardial oxygen demand and oxygen supply caused by coronary artery occlusion or impending occlusion. Acute coronary syndrome refers to a series of symptoms caused by acute myocardial ischemia, including myocardial infarction (ST-segment elevation and depression, Q wave type and no Q wave type) and unstable angina. Clinical studies have found that angina symptoms in 50-60% of patients with coronary heart disease can disappear after resection of sympathetic ganglia such as superior cervical ganglion (SCG) and stellate ganglion (SG), suggesting that the innervation of the heart Sympathetic involvement in myocardial ischemic injury response. The ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/00A61P9/10A61P9/12A61P25/00
Inventor 梁尚栋李桂林刘俊孔繁君刘双梅涂桂花彭海英徐宏
Owner NANCHANG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com